ATOS
Healthcare BiotechnologyAtossa Therapeutics, Inc.
$2.34
+0.07 +3.08% today
Price History
Not enough data
Key Stats
Market Cap
23.35M
Avg Volume
74,403
EPS
-$4.45
52W High
$19.35
52W Low
$1.70
Div. Yield
0.0%
Analyst Ratings
Buy1
Str Buy
1
Buy
0
Hold
0
Sell
0
Str Sell
Valuation
Forward P/E
-0.71
P/B Ratio
0.87
EV/EBITDA
0.07
Margins
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(89.2%)
Return on Assets
(50.7%)
Liquidity & Leverage
Current Ratio
5.69
Quick Ratio
4.79
Total Cash
26.09M
Total Debt
0
About
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
www.atossatherapeutics.com